Atlas wraps Arteaus story with $260M royalty sale as Emgality sales inches upward
Six months after Eli Lilly notched a second-runner-up approval for its CGRP migraine drug Emgality, the Atlas-founded biotech that brought it over the proof-of-concept gate five years ago has sold all its royalty interest for $260 million.
In Arteaus’ “final chapter” — as Atlas partner Bruce Booth calls it — the now-defunct biotech handed Royalty Pharma all proceeds it would earn on future global net sales of Emgality. The deal marks the final monetization from Arteaus, which ceased operations as an independent entity after Eli Lilly bought back rights to the drug in 2014.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.